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Objectives: The aim of this study was to comprehensively evaluate the antibacterial activity and MurE inhibition
of a set of N-methyl-2-alkenyl-4-quinolones found to inhibit the growth of fast-growing mycobacteria.
Methods: Using the spot culture growth inhibition assay, MICs were determined for Mycobacterium tuberculosis
H37Rv, Mycobacterium bovis BCG and Mycobacterium smegmatis mc
2155. MICs were determined for Mycobac-
terium fortuitum, Mycobacterium phlei, methicillin-resistant Staphylococcus aureus, Escherichia coli and Pseudo-
monas aeruginosa using microplate dilution assays. Inhibition of M. tuberculosis MurE ligase activity was
determined both by colorimetric and HPLC methods. Computational modelling and binding prediction of the
quinolones in the MurE structure was performed using Glide. Kinetic experiments were conducted for under-
standing possible competitive relations of the quinolones with the endogenous substrates of MurE ligase.
Results: The novel synthetic N-methyl-2-alkenyl-4-quinolones were found to be growth inhibitors of M. tuber-
culosis and rapid-growing mycobacteria as well as methicillin-resistant S. aureus, while showing no inhibition for
E. coli and P. aeruginosa. The quinolones were found to be inhibitory to MurE ligase of M. tuberculosis in the
micromolar range (IC50  40–200 mM) when assayed either spectroscopically or by HPLC. Computational
docking of the quinolones on the published M. tuberculosis MurE crystal structure suggested that the uracil rec-
ognition site is a probable binding site for the quinolones.
Conclusions: N-methyl-2-alkenyl-4-quinolones are inhibitors of mycobacterial and staphylococcal growth, and
show MurE ligase inhibition. Therefore, they are considered as a starting point for the development of increased
afﬁnity MurE activity disruptors.
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Introduction
Tuberculosis (TB) is a contagious disease caused by infection with
species belonging to the Mycobacterium tuberculosis complex.
1
This slow-growing acid-fast bacterium exerts a tremendous
impact on current global health.
2 Staphylococcus aureus is also
a major concern, as this pathogen is the most common cause
of bacterial infection worldwide
3 and methicillin-resistant
S. aureus (MRSA) strains remain difﬁcult to treat,
4 despite the
approval of agents such as linezolid, quinupristin/dalfopristin
and daptomycin over the last decade. Infection with drug-resist-
ant M. tuberculosis strains is extremely serious, prolonging
# The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
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1766treatment time, decreasing the probability of cure and increasing
the cost of treatment.
5 The current anti-TB chemotherapy must
be administered for 6 months for drug-susceptible strains and
for ≥2 years for multidrug-resistant (MDR) or extensively drug-
resistant (XDR) infections. Outbreaks of drug-resistant pathogens
are more and more frequent everywhere, and it would be cata-
strophic if these pathogens develop total drug resistance.
6,7
Novel chemical entities are therefore required for treating drug-
resistant strains. They must be potent enough to reduce the
length of treatment and to prevent the emergence of resistance,
but they must also be safer than second-line drugs and not inter-
fere with antiretroviral therapy.
8 Screening for novel mechanisms
of action seems a reasonable strategy to develop inhibitors
against MDR, XDR and totally drug-resistant strains of M. tubercu-
losis, as the resulting compounds may have a disrupting effect
on pathways or enzymes that have never been targeted before.
Natural products are a primordial source of bioactive chemical
scaffolds that have been therapeutically exploited for a large
number of diseases.
9 Plants and microorganisms have developed
many successful secondary metabolites for protection against
microbial infection. Antibiotics are, by deﬁnition, produced by
microorganisms
10 and are one of the most valuable antimicrobial
classes, as they gained bacteria-killing competence by targeting
essential biochemical pathways through centuries of microbial
evolution. b-Lactams, glycopeptides, bacitracin, fosfomycin and
cycloserine are all antibiotics targeting the peptidoglycan biosyn-
thetic pathway.
11 Peptidoglycan is an essential bacterial cell wall
polymer that is responsible for cell shape and serves as contain-
ment for cytoplasmic pressure. Because it is a well-validated
pathway, there is growing interest in developing small molecule
inhibitors that target novel proteins of this biosynthetic route.
12
Mycobacterial peptidoglycan is the sustaining mesh that
supports the mycolyl-arabinogalactan complex and is therefore
considered an indispensable building block.
13 Mur ligases are
cytoplasmic enzymes that perform the biosynthesis of uridine-
diphosphate-N-acetylmuramyl-L-Ala-D-Glu-m-DAP-D-Ala-D-Ala
(UDP-MurNAc-pentapeptide) from uridine-diphosphate-N-acetyl-
glucosamine (UDP-NAcGlc).
14 ATP-dependent Mur ligases C, D, E
and F are able to sequentially add the amino acids forming the
pentapeptide chain, and have been shown to act by a similar
mechanism to folylpolyglutamate synthetase.
15 The MurE ligase
of M. tuberculosis preferentially adds meso-diaminopimelic acid
(m-DAP) to the g-carboxyl group of glutamic acid in UDP-
MurNAc-L-Ala-D-Glu.
16,17 Natural product inhibitors have been
already reported by us
18 and increasing efforts are being made
to develop speciﬁc inhibitors of this enzyme.
The approach used in this work was to comprehensively
evaluate the bioactivity of ﬁve synthetic evocarpine-related qui-
nolones. The compounds belonging to this class have been
shown to be effective inhibitors of rapid-growing Mycobacterium
species.
19 N-methyl-2-alkenyl-4-quinolones were tested against
slow- and rapid-growing mycobacterial species (M. tuberculosis
H37Rv, Mycobacterium bovis BCG, Mycobacterium smegmatis,
Mycobacterium fortuitum and Mycobacterium phlei). The antibac-
terial activity was also recorded against two epidemic strains of
commonly prevalent MRSA (EMRSA-15 and -16) and two Gram-
negative bacteria and the cytotoxicity was evaluated against
murine macrophages, in order to assess the speciﬁcity of the qui-
nolones in whole cell experiments. In our in-house MurE screen-
ing programme of potential inhibitors, these quinolones were
shown to inhibit M. tuberculosis MurE ligase activity when
assayed colorimetrically. This ﬁnding was further conﬁrmed by
HPLC quantiﬁcation of UDP-MurNAc-tripeptide, the product of
the MurE reaction. The quinolones were computationally mod-
elled and docked into the published M. tuberculosis MurE
protein X-ray structure (PDB:2wtz) to propose a probable
binding site. The docking results and the competition exper-
iments of quinolone 2 with MurE ligands suggest that they
bind to a speciﬁc hydrophobic pocket close to the uracil-
binding site that could be exploited to generate a novel class
of antimycobacterials.
Materials and methods
Reagents
Isoniazid, norﬂoxacin, kanamycin, resazurin, Tween 80, glycerol, m-DAP,
ATP, bis-trispropane, magnesium chloride, Luria–Bertani broth, Mueller–
Hinton broth, RPMI-1640, L-glutamine, heat-inactivated fetal calf
serum, DMSO and ammonium formate were purchased from Sigma–
Aldrich. Middlebrook 7H9, Middlebrook 7H10, and oleic acid, albumin,
dextrose and catalase supplement (OADC) were obtained from BD Diag-
nostics. The MurE substrate UDP-MurNAc-L-Ala-D-Glu was purchased from
the BaCWAN synthetic facility (University of Warwick, UK).
Synthesis of N-methyl-2-alkenyl-4-quinolones 1–5
The N-methyl-2-alkenyl-4-quinolones 1–5 were obtained using a syn-
thetic route recently reported.
19 The quinolone alkaloids with a cis-unsa-
turated aliphatic side chain (1 and 2) were prepared by the reaction of
cis-unsaturated methyl ketones with N-methyl isatoic acid anhydride in
the presence of lithium diisopropylamide (LDA). Trans-a,b-unsaturated
methyl ketones were used to prepare alkaloids 3–5 using the same
type of condensation with N-methyl isatoic acid anhydride in the pres-
ence of LDA. The identity of the quinolone alkaloids and their correspond-
ing intermediates was conﬁrmed by analysis of 1D- and 2D-NMR
spectroscopy and liquid chromatography–electrospray ionization–mass
spectrometry data. Spectroscopic data of quinolones 1–5 are provided
as Supplementary data at JAC Online.
Bacterial strains and cells
M. tuberculosis H37Rv (ATCC 27294), M. bovis BCG (ATCC 35734), M. smeg-
matis mc
2155 (ATCC 700084), M. fortuitum (ATCC 6841), M. phlei (ATCC
11758), Escherichia coli JM109 (ATCC 53323), Pseudomonas aeruginosa
(ATCC 25668) and murine RAW264.7 macrophages (ATCC TIB71) were
used in this study. EMRSA-15 and -16 were gifts from Dr Paul Stapleton
(School of Pharmacy, University of London, UK). Competent E. coli
BL21(DE3)pLysS cells (New England Biolabs, UK) were used for overprodu-
cing MurE ligase of M. tuberculosis H37Rv.
Drug susceptibility
The spot culture susceptibilityassay for M. tuberculosis H37Rv, M. bovisBCG
and M. smegmatis mc
2155 species was performed as described pre-
viously.
20 Brieﬂy, Middlebrook 7H9 mycobacterial cultures were serially
diluted to 10
5 cfu/mL. A 5 mL aliquot of the diluted culture ( 500 viable
cells) was spotted onto 5 mL of solidiﬁed Middlebrook 7H10 agar
medium,supplementedwith10%(v/v)OADCinasix-wellplatecontaining
various concentrations of compounds 1–5. A negative control containing
only DMSO was included in each plate. A six-well plate containing various
concentrations of isoniazid was also used as a positive control. Following
incubation at 378C for 2 weeks for slow growers and 3 days for M.
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was no visible mycobacterial growth. Microdilution-based methods using
Mueller–Hinton broth for S. aureus, and Luria–Bertani broth for E. coli
and P. aeruginosa were employed for the MIC determination of the quino-
lones.
18 Kanamycin and norﬂoxacin were used as positive controls. Sus-
ceptibilities of M. fortuitum and M. phlei were assessed as reported
previously
21 in a microdilution assay in cation-adjusted Mueller–Hinton
broth using isoniazid as a positive control.
Cytotoxicity towards RAW264.7 macrophages
RAW264.7 macrophages (National Collection of Type Cultures) were
maintained in RPMI-1640 medium supplemented with 2 mM L-glutamine
and 10% heat-inactivated fetal calf serum, in a humidiﬁed incubator con-
taining 5% CO2,a t3 7 8C, and passaged twice before the assay. The cell
suspension was adjusted to 5×10
5 cells/mL and the assay was per-
formed in 96-well cell culture ﬂat-bottom plates (Costar 3596; VWR) in
triplicate. Firstly, 2 mL of the 10 g/L stock solution of compounds 1–5
was added to 200 mL of RPMI-1640 medium in the ﬁrst row and then
2-fold serially diluted. In each well, 100 mL of diluted macrophage cells
was added. After 48 h of incubation, the monocytes were washed
twice with PBS and fresh RPMI-1640 medium was added. The plates
were then revealed with 30 mL of a freshly prepared and ﬁlter-sterilized
aqueous 0.01% resazurin solution, and incubated overnight at 378C.
The following day, ﬂuorescence was measured at 590 nm with excitation
at 560 nm using a Fluostar Optima microplate reader (BMG LABTECH).
MurE ligase inhibition assay
The MurE protein of M. tuberculosis was overexpressed in E. coli
BL21(DE3)pLysS and puriﬁed as previously reported.
17,18 The phosphate
colorimetric detection method was performed for the preliminary
screen of the small molecules. Additionally, M. tuberculosis MurE inhi-
bition was assayed using HPLC analysis. A solution containing 25 mM
bis-trispropane buffer (pH 8.5), 5 mM MgCl2, 100 mM UDP-MurNAc-dipep-
tide, 250 mM ATP and 1 mM m-DAP was prepared in water as the
enzyme–substrate mixture. Quinolones 1–5 were dissolved in DMSO at
a concentration of 25, 8.3, 2.5, 0.83, 0.25 and 0.083 mM, and 2 mL was
dispensed into 0.5 mL Eppendorfs. MurE enzyme was added to the
enzyme–substrate mixture at a ﬁnal concentration of  40 nM, and
48 mL of the mixture was rapidly added to each Eppendorf and incubated
at 378C for 30 min. The reaction was stopped by denaturing the protein
at 1008C using a block heater for 10 min. The content was centrifuged
for homogenization at 4000 rpm for 30 s and then transferred to
200 mL glass inserts (Supelco) ﬁtted to HPLC vials that were analysed
directly by HPLC (Agilent 1100 series) using an octadecylsilane RP-18
column (4.6 mm×250 mm×5 mm, Jones chromatography) eluting iso-
cratically with a buffer of 50 mM ammonium formate (pH 4.0) and at
a ﬂow rate of 0.5 mL/min. The products of the reaction were detected
at 268 nm and 220 nm simultaneously using a diode array detector
system. A calibration curve was constructed for the tripeptide and
conﬁrmed a good linearity (R
2¼0.9978) of the signal at 268 nm to the
concentration of UDP-MurNAc-tripeptide. Activity controls at 0%
(without enzyme) and 100% (with enzyme) were included.
Docking the MurE protein structure
The protein was prepared using the protein preparation wizard of the
Maestro software (Schro ¨dinger Software Suite 2009) from the PDB:2wtz
ﬁle downloaded from the RCSB Protein Data Bank web site (http://pdb.
org/pdb/explore/explore.do?structureId=2wtz). Chain B was selected
and the peptide plane of Thr-298 was rotated to prevent overlapping
with His-307. All of the residues were left charged as expected at a
working pH of 8.5, except for Glu-198, which was set uncharged. The
modiﬁed residue N6-carboxylysine-262 was appropriately recognized.
The docking grid was built as a centroid of 30 A ˚, choosing the residues
fundamental for the binding of the substrate according to the PDBsum
LigPlot diagram,
22 such as Ala-69, Thr-85, Thr-86, Thr-195, Glu-198,
Ser-222 and His-248. The ligands 1–5 were drawn using Chemdraw, con-
verted into sdf format with BabelGUI and, lastly, were all processed using
LigPrep at pH 8.5+1.0. Docking was performed with Glide
23 using stan-
dard precision scoring and varying amide bond conformations.
Kinetic competition assays
Different concentrations of 2 (1000, 300, 100, 30 and 0 mM) were
prepared separately with different concentrations of the MurE sub-
strates: UDP-MurNAc-dipeptide (300, 100, 30, 10 and 3 mM); m-DAP
(300, 100, 30, 10 and 3 mM); and ATP (300, 100, 30, 10 and 3 mM).
The formation of the UDP-MurNAc-tripeptide product was followed
by HPLC after 30 min of reaction. The conditions of the reaction and
the analytical system were exactly the same as those described
earlier for the HPLC inhibition assay. The experiments were performed
in duplicate, and the total amount formed was calculated from the
area under the peak (retention time  7 min) using the calibration
curve and divided by the time (30 min) to obtain the velocity in
mM/min.
Results
Bacterial growth inhibition and cytotoxicity
All of the synthesized N-methyl-2-alkenyl-4-quinolones (1–5)
(Figure 1a) were signiﬁcantly active in susceptibility testing on
rapid-growing mycobacteria. They also showed growth inhibition
of slow-growing mycobacteria (M. tuberculosis H37Rv and
M. bovis BCG), having an MIC value between 5 and 25 mg/L
(Table 1). The quinolones were more active against rapid-
growing species, showing an MIC value between 0.5 and
10 mg/L. The growth of the highly problematic EMRSA strains
was also notably inhibited, revealing MIC values in the range of
0.5–4 mg/L. Moreover, the quinolones did not show any signiﬁ-
cant inhibition at 50 mg/L for E. coli, behaving similarly to the
control, isoniazid. The MIC values of 1–5 for E. coli were
.1000 mg/L and for P. aeruginosa they were .256 mg/L.
These compounds were moderately cytotoxic towards macro-
phage RAW264.7 cells, having a 50% growth inhibition concen-
tration (GIC50) of between 24 and 112 mg/L (Table 1). The
selectivity index (SI), deﬁned as the GIC50 value divided by the
MIC, varied between 1.0 and 5.6 for M. tuberculosis, but was
much higher for S. aureus (SI: 9.75–112).
M. tuberculosis MurE ligase inhibition
MurE ligase activity in the presence of compounds was assayed
by HPLC quantiﬁcation of the product (UDP-MurNAc-L-Ala-D-Glu-
m-DAP) formed after 30 min and by the phosphate colorimetric
detection method. Clearly, all of quinolones 1–5 showed inhi-
bition of MurE [Figures 1b and S1 (Figure S1 is available as Sup-
plementary data at JAC Online)], displaying an IC50 value of
95–207 mM when determined by HPLC and of 36–72 mM when
analysed by the phosphate detection colorimetric method
(Table 1). Quinolone 2 was the most active MurE inhibitor, with
an IC50 value of 95 mM, as can be inferred from the chromato-
grams at different concentrations of the inhibitor (Figure 1b).
The difference between the MurE inhibition values determined
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all of the quinolones.
Docking of the quinolones in the MurE structure
The MurE substrate UDP-MurNAc-L-Ala-D-Glu used as a self-dock
test
23 was effectively docked in the same orientation as the pub-
lished MurE-substrate crystal structure (PDB:2wtz), displaying a
GlideScore of 29.92 kcal/mol. The root mean square distance
of the heavy atoms of the UDP-MurNAc-L-Ala-D-Glu substrate in
the docked and crystal structures was 3.09 A ˚, indicating a
good preparation of the protein and adequate docking par-
ameters. Our results suggested that all of the quinolones inter-
acted in a similar fashion to a pocket located near the uracil
recognition site (Figure 2a) of the Rossmann fold in domain 1
of MurE.
14 According to the calculated hydrophilicity surface of
the protein (Figure 2b), the quinolone was attracted to the lipo-
philic patches on the protein surface. The GlideScore for quino-
lones 1–5 was in the range of 22.46 to 24.51 kcal/mol, with
quinolone 4 having the highest score in absolute value. This
range indicated a rather weak binding, as can be observed in
the orientations with a single hydrogen bond participating in
the interaction (via the hydroxyl group of Thr-176 to the tertiary
nitrogen atom of the quinolone in Figure 2c).
Kinetic competition between the quinolones
and MurE substrates
The velocity of formation of the MurE product in the presence of
quinolone 2 displayed a dependence on the concentration of the
UDP-MurNAc-dipeptide substrate. At a high concentration of
UDP-MurNAc-dipeptide (300 and 100 mM), the velocity decreased
with an increase in the concentration of the quinolone
(Figure 3a). For these two concentrations, the ﬁtted lines con-
verge to a point of intersection, therefore indicating competitive
inhibition between the UDP-MurNAc-dipeptide and the quino-
lone.
24 However, at a low concentration of UDP-MurNAc-dipep-
tide (30, 10 and 3 mM), the velocity of MurE product formation
was independent of the concentration of the quinolone. For the
two other substrates, namely ATP (Figure 3b) and m-DAP
(Figure 3c), the change in the velocity was less drastic when
varying the concentration of the quinolone, and the curves had
the same tendency without converging to a point of intersection,
indicating uncompetitive inhibition.
24
Discussion
Initially isolated as the active antimycobacterial entities from the
fruits of the traditional Chinese medicinal tree Evodia rutaecarpa
(Rutaceae),
25 the N-methyl-2-alkenyl-4-quinolone chemotype
was further exploited by synthetic methods in order to explore
chemical variation and improve activity.
19 A group of these
chemical entities, which showed the highest activity on rapidly
growing mycobacteria, were selected for a comprehensive bio-
logical evaluation. We found that these compounds were
growth inhibitors of mycobacterial species and the highly proble-
matic EMRSA strains, being also inhibitors of the MurE ligase of
M. tuberculosis. The MIC indicated that these compounds are
notable antibacterials, particularly against EMRSA-15 and -16,
which are regularly encountered in UK hospitals.
26 The macro-
phage SI in relation to the H37Rv strain for the quinolones was
considerably low (SI,10);
27 however, the SI in relation to
EMRSA-15 and -16 was much higher (SI range 9.75–112), indi-
cating a promising selectivity. Moreover, the compounds did
not show inhibition of E. coli growth up to a high dose and
they are probably innocuous to bacterial gut ﬂora. It was also
noted that the cytotoxicity was reduced when the linear
alkenyl chain was extended, suggesting an interesting relation
for differential selectivity.
The 4-quinolone nucleus is a speciﬁc class of compound that
has attracted and continues to attract signiﬁcant interest from
the pharmaceutical industry, principally because of the impact
of the ﬂuoroquinolones, which inhibit both DNA gyrase and
topoisomerase IV,
28 and the anticancer 2-phenyl-4-quinolones
targeting tubulin.
29 In comparison to the ﬂuoroquinolones, the
compounds of the present study lack a carboxyl group at position
C-3, which is considered to be essential for DNA gyrase inhi-
bition,
30 and therefore a further mechanism of action must be
assumed. Moreover, this class of chemicals may also be
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Figure 1. Structure of N-methyl-2-alkenyl-4-quinolones 1–5 and
isoniazid (INH), and HPLC MurE inhibitory activity of quinolone 2. (a)
Chemical structure of the synthesized quinolones showing the
modiﬁcations on the alkenyl chain. (b) HPLC chromatograms at 268 nm
of the product (UDP-MurNAc-tripeptide) and the substrate (UDP-
MurNAc-dipeptide) of the reaction catalysed by M. tuberculosis MurE in
the presence of different concentrations of quinolone 2.
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JACexploited for the discovery and development of bacterial Mur
ligase inhibitors. Using both colorimetric and HPLC methods, it
was found that the compounds reproducibly inhibited in vitro
the ligase activity of MurE from M. tuberculosis. Comparing
1 and 2, a slight inﬂuence on MurE inhibition was observed for
the position of the double bond in the alkenyl chain. Furthermore,
the percentage of inhibition when determined using the
phosphate colorimetric method was slightly higher than when
compared with the HPLC method, probably because of a small
decoupling between phosphatase and ligase activities.
For the computational prediction of the binding of potential
ligands to a protein, it is advisable to use a 3D structural
model of atomic resolution,
31 typically below 2 A ˚. However, in
the absence of structures of MurE from M. tuberculosis below
2A ˚ resolution, we used the available published model at 3 A ˚
as a preliminary basis for assessing probable binding sites. Inter-
estingly, quinolones 1–5 were predicted to bind to a hydrophobic
pocket located near the uridine recognition site in domain 1 of
the enzyme. The GlideScore was low ( 24 kcal/mol) in compari-
son with general reported values for inhibitors ( 210 kcal/
mol);
32 however, considering the weak interactions between
the quinolones and the protein, it is not surprising to observe
low GlideScore values. This also indicates that there is space
for improvement in the search for chemical and steric comple-
mentarities, and the possibility of using this lipophilic cavity for
rational drug design. We hypothesize that the aliphatic lipophilic
chain of 1–5 interacts with the buried hydrophobic residues
of MurE ligase, probably inducing a change in the conformation
that prevents binding to UDP-MurNAc-dipeptide. In order to
gain further evidence of this possibility, a kinetic competition
experiment showed that at a low concentration of the
dipeptide, the velocity of the reaction was unaltered by the
concentration of the inhibitor. At low concentration of the dipep-
tide substrate, the majority of the enzyme was free and,
(a)
(b) (c)
Figure 2. Lowest GlideScore docking pose of quinolone 4 interacting with
MurE (PDB:2wtz) of M. tuberculosis.
17 (a) Presumed binding pocket of the
quinolones (in yellow) near the uracil recognition site of UDP-MurNAc-
dipeptide (in magenta). (b) Protein surface showing the high
hydrophobicity (in red) of the quinolone binding pocket calculated using
UCSF Chimera software.
34 (c) MurE residues that may interact with the
quinolones: Thr-176, Ala-168, Gln-45, His-66 and Thr-61. This ﬁgure
appears in colour in the online version of JAC, and in black and white in
the print version of JAC.
Table 1. MICs for different species of bacteria, GIC50 and SI for macrophage cells and MurE IC50 of the synthetic quinolones 1–5
Compound
MIC in mg/L (mM)
Murine
macrophages
M. tuberculosis
MurE
M. tuberculosis
H37Rv M. bovis BCG
M. smegmatis
mc
2155 M. fortuitum M. phlei
S. aureus
GIC50
(mg/L) SI
IC50 (mM)
EMRSA-15 EMRSA-16
phosphate-
based method
HPLC
method
1 25 (70.7) 10 (28.3) 10 (28.3) 0.5 (1.41) 0.5 (1.4) 1 (2.8) 0.5 (1.4) 24+9 1.0 52+22 159+6
2 10 (28.3) 10 (28.3) 10 (28.3) 1 (2.83) 1 (2.8) 1 (2.8) 0.5 (1.4) 39+12 3.9 36+16 95+9
3 25 (84.0) 25 (84.0) 5 (16.8) 2 (6.72) 1 (3.4) 4 (13.4) 2 (6.72) 39+11 1.6 70+25 207+6
4 10 (30.7) 5 (15.3) 5 (15.3) 1 (3.06) 0.5 (1.5) 2 (6.12) 2 (6.12) 40+7 4.0 72+23 187+8
5 20 (58.9) 10 (29.4) 10 (29.4) 1 (2.94) 1 (2.9) 2 (5.8) 1 (2.9) 112+10 5.6 52+20 140+5
Isoniazid 0.1 (0.73) 0.1 (0.73) 5 (18.5) 1 (3.65) 4 (15) ND ND .500 .5000 .1000 .1000
ND, not determined.
The MIC of norﬂoxacin was 0.5 and 256 mg/L for EMRSA-15 and -16, respectively.
The SI was calculated by dividing the GIC50 by the MIC for M. tuberculosis H37Rv.
IC50 and GIC50 values are shown +SD.
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MurE enzyme has low interaction with the quinolones. However,
when the concentration of the dipeptide substrate was high,
most of the enzyme formed the enzyme–substrate complex,
which, in agreement with the induced-ﬁt theory,
33 has a differ-
ent protein conformation. Our results suggested that this
induced-ﬁt enzyme–substrate conformation of MurE interacted
with the quinolones and when this conformation occurred, inhi-
bition of ligase activity took place. This novel type of MurE inhibi-
tor can be included as a starting point in virtual and fragment
screening MurE projects that may help in the detection of struc-
ture–activity relationships. Structural modiﬁcations of a particu-
larly interesting MurE inhibitor pharmacophore can potentially
lead to potent and selective antibacterials in the near future.
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